161609-80-9

Basic information

• Product Name: 4-HYDRAZINOCARBONYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER
• Synonyms: 4-HYDRAZINOCARBONYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;1,4-Piperidinedicarboxylic acid, 1-(phenylMethyl) ester, 4-hydrazide;1-CBZ-piperidine-4-carboxylhydrazide;1-N-Cbz-piperidine-4-carboxylic acid hydrazide
• CAS NO: 161609-80-9
• Molecular Formula: C₁₄H₁₉N₃O₃
• Molecular Weight: 277.32
• Mol File: 161609-80-9.mol

Chemical Properties

• Boiling Point: 498.3±44.0 °C(Predicted)
• Appearance: /
• Density: 1.243±0.06 g/cm3(Predicted)
• PKA: 13.01±0.20(Predicted)
• CAS DataBase Reference: 4-HYDRAZINOCARBONYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDRAZINOCARBONYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(161609-80-9)
• EPA Substance Registry System: 4-HYDRAZINOCARBONYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(161609-80-9)

Safety Data

• Hazardous Substances Data: 161609-80-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-HYDRAZINOCARBONYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as a muscarinic M1 receptor agonist for treating muscarinic M1/M4 receptor mediated diseases. Its agonistic activity on these receptors can help in the management and treatment of various conditions related to the muscarinic system, such as Alzheimer's disease, overactive bladder, and certain cardiovascular disorders.

Upstream product

• 160809-38-1 1-benzyl 4-ethyl piperidine-1,4-dicarboxylate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 1126-09-6 4-carbethoxypiperidine 
• 501-53-1 benzyl chloroformate 
• 138163-07-2 piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-methyl ester 

Downstream Products

• 1257543-21-7 C₂₁H₂₃ClN₄O₃S 
• 1293303-51-1 C₂₈H₃₅N₇O₄ 

Relevant articles and documents

TBSOTf-promoted versatile N-formylation using DMF at room temperature

Hydrazides and amines were N-formylated by DMF in the presence of tert-butyldimethylsilyl triflate (TBSOTf) at room temperature, in good to excellent yields.

BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1 , R2, R3 and R4 are as defined herein.

AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION

Azaindazole compounds are useful for treating Flaviviridae virus infection, including HCV infection.

AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS

The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

Aryl substituted heterocycles

The present invention concerns the novel use of aryl substituted heterocycles of formula I, set out below, which antagonize the pharmacological actions of one of ent endogenous neuropeptide tachykinins an the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment. Certain novel aryl substituted heterocycles of formula I and novel intermediates for their manufacture are also provided. STR1